Paper · 2026 · Open access

Review On AI Drug Discovery or Development

Nikhil Sharma*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Pardeep Kaur

Zenodo (CERN European Organization for Nuclear Research) · Published 16 September 2026 · DOI 10.5281/zenodo.22796789

Read the free full textCite this paper

In brief

“Review On AI Drug Discovery or Development” is a 2026 paper by Nikhil Sharma*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Pardeep Kaur, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
0
Authors
1

Abstract

Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, particularly in medicinal chemistry and drug discovery. Traditional drug development is a complex, time-consuming, and costly process with a low success rate, often requiring extensive experimentation and significant financial investment. AI techniques, including Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and Neural Networks (NN), offer innovative solutions to overcome these challenges by enabling efficient analysis of large datasets, accelerating target identification, optimizing lead compounds, and predicting drug efficacy and toxicity. AI-driven tools such as virtual screening, Quantitative Structure–Activity Relationship (QSAR) modeling, and predictive analytics have significantly improved the speed and accuracy of drug discovery processes. Furthermore, AI applications extend beyond drug discovery to pharmaceutical manufacturing, clinical trial design, market prediction, and product cost analysis, enhancing operational efficiency and decision-making. Generative AI technologies, including Generative Adversarial Networks (GANs), are also revolutionizing data generation, medical imaging, and personalized medicine. Despite its advantages, the adoption of AI in the pharmaceutical sector faces challenges such as data quality limitations, ethical concerns, interpretability issues, and regulatory uncertainties. Nevertheless, the integration of AI with traditional experimental methods holds great promise for improving drug development efficiency, reducing costs, and delivering safer and more effective therapies to patients.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kaur, N. S. R. K. A. P. S. A. P. S. P. (2026). Review On AI Drug Discovery or Development. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22796789

MLA 9

Kaur, Nikhil Sharma*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Pardeep. “Review On AI Drug Discovery or Development.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.22796789.

Chicago

Kaur, Nikhil Sharma*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Pardeep. 2026. “Review On AI Drug Discovery or Development.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22796789.

Harvard

Kaur, N. S. R. K. A. P. S. A. P. S. P. (2026) ‘Review On AI Drug Discovery or Development’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.22796789.

IEEE

N. S. R. K. A. P. S. A. P. S. P. Kaur, “Review On AI Drug Discovery or Development,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.22796789.

BibTeX

@article{kaur2026review,
  title     = {{Review On AI Drug Discovery or Development}},
  author    = {Kaur, Nikhil Sharma*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Pardeep},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.22796789},
  url       = {https://doi.org/10.5281/zenodo.22796789}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence in drug discovery
  • machine learning
  • deep learning
  • virtual screening
  • QSAR models
  • generative adversarial networks
  • generative AI
  • drug toxicity prediction

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Kaur, N. S. R. K. A. P. S. A. P. S. P. (2026). Review On AI Drug Discovery or Development. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22796789

How many times has this paper been cited?

0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Zenodo (CERN European Organization for Nuclear Research).

Who wrote this paper?

Nikhil Sharma*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Pardeep Kaur.

What is the DOI of this paper?

10.5281/zenodo.22796789. The permanent link is https://doi.org/10.5281/zenodo.22796789.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.